

9586 '05 SEP -2 A9:42

19 Hughes Irvine, CA 92618 Toll Free: 800.729.9991 Telephone: 949.455.4700 Fax: 949.855.8210 www.sicor.com

August 31, 2005

Division of Dockets Management Food and Drug Administration 5630 Fishers Lane, Room 1061 (HFA-305) Rockville, MD 20852

RE: Docket No. 1999P-0796/PSA1

Dear Madam or Sir:

The above referenced petition for stay of action, submitted by Astra-Zeneca in 1999, pertains to abbreviated new drug applications (ANDAs) for propofol in a formulation that contains no antimicrobial additive. Astra-Zeneca's petition for stay of action makes particular reference to an ANDA of SICOR Pharmaceuticals (formerly Gensia Sicor Pharmaceuticals), namely ANDA 75-433.

At the request of the Agency this letter is submitted to the public docket, and acknowledges that ANDA 75-433 was withdrawn by SICOR in 2000, and that our company currently has no application approved or pending before the agency for a propofol product without an antimicrobial additive.

If additional information is needed, please contact me at (949) 457-2808 or by facsimile at (949) 583-7351.

Sincerely,

Rosalie A. Lowe

Director, Regulatory Affairs

Rosalie a. Some

S \PRO75433\CORRESPD\08-31-05 Ack ltr that 74-433 was withdrawn doc

1999P-0796

LET 1